Study identifier:D5551R00015
ClinicalTrials.gov identifier:NCT05663515
EudraCT identifier:N/A
CTIS identifier:N/A
EXCEED - A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients who Initiated Exenatide as Compared with those who Initiated Other non-Glucagon-Like Peptide 1 Receptor Agonists based Glucose Lowering Drugs
Pancreatic Cancer
N/A
No
Exenatide, Non-GLP-1 RA based glucose lowering drugs
All
24000
Observational
18 Years - 99 Years
Allocation: N/A
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: -
Verified 01 Dec 2024 by AstraZeneca
AstraZeneca
IQVIA Ltd
No locations available
Arms | Assigned Interventions |
---|---|
Initiators of exenatide Patients with T2DM, aged 18 years or older, who initiated treatment with exenatide during the study period, 2006 to 2023 | Drug: Exenatide All patients initiating exenatide during the study period will be identified by ATC codes and be included in the exenatide group in a hierarchical manner, regardless of previous use of non-GLP-1 RA based glucose lowering drugs. Other Name: BYETTA, BYDUREON/BYDUREON BCise |
Initiators of non-GLP-1 RA based glucose lowering drugs Patients with T2DM, aged 18 years or older, who initiated treatment with non-GLP-1 RA based glucose lowering drugs during the study period, 2006 to 2023 | Drug: Non-GLP-1 RA based glucose lowering drugs Initiators of non-GLP-1 RA based GLDs with no use of exenatide before or during the study period. Other Name: Insulin/analogues (excl. A10AE54, A10A56), Biguanide, Sulfonylurea, Sulfonamide (heterocycl.), combined oral GLD (excl. DPP-4i), Alpha glucose inhib., Thiazolidinedione, SGLT2i, Oth. GLD excl. insulin |